How Ipamorelin Affects TSH and Thyroid Function

GH peptides can affect thyroid function through the GH/IGF-1 axis and its downstream effects on thyroid hormone metabolism. Ipamorelin is not directly thyrotoxic, but its GH elevation creates indirect thyroid effects:

1. Type 1 deiodinase upregulation: GH and IGF-1 increase the activity of type 1 deiodinase (D1) in the liver and kidneys. D1 is the enzyme that converts the prohormone T4 (thyroxine) to the active hormone T3 (triiodothyronine). Increased D1 activity accelerates T4-to-T3 conversion.
2. T4 depletion and compensatory TSH rise: If the rate of T4 conversion to T3 exceeds the thyroid gland's ability to produce replacement T4, circulating free T4 declines. The hypothalamic-pituitary-thyroid (HPT) axis detects this T4 decline and responds by increasing TSH secretion. This is the subclinical hypothyroidism pattern: elevated TSH with low-normal or mildly low free T4 and potentially normal or initially elevated free T3.
3. Epidemiological context: Smyczynska et al. (2010, PMID 20307267) reported a 23% incidence of transient TSH elevation in children receiving recombinant human GH therapy. This represents a high-GH-burden paediatric population with a known predisposition to thyroid vulnerability. Adult studies with lower GH burden show substantially lower rates; Losa et al. (2008, PMID 19012473) observed thyroid changes in adults at a lower incidence than the paediatric data. Ipamorelin produces lower and more pulsatile GH elevation than daily rhGH, suggesting thyroid impact probability is correspondingly lower.
4. Sermorelin comparison: Sermorelin's FDA prescribing information documents a 6.5% subclinical hypothyroidism rate. Ipamorelin lacks equivalent regulatory prescribing data, but produces lower average daily GH exposure than sermorelin-driven continuous stimulation protocols, suggesting lower thyroid risk.
5. Individual vulnerability: Users with borderline thyroid function, Hashimoto's thyroiditis, positive TPO antibodies, or prior thyroid pathology are at higher risk for GH-mediated T4 depletion.

Standard ipamorelin protocol (200-300 mcg SC, 1-2 times daily):

• TSH: expected to remain in normal range (0.4 to 4.0 mIU/L) for most users; rare subclinical elevation possible in vulnerable individuals
• Free T4: may decline mildly toward the lower end of the reference range; frank free T4 suppression is uncommon
• Free T3: may transiently increase (more T4 converted to T3) before normalising if thyroid compensates adequately

Estimated risk context:

• Sermorelin (GHRH analog with daily use): 6.5% subclinical hypothyroidism (FDA prescribing information)
• Recombinant human GH (paediatric): 23% transient TSH elevation (Smyczynska 2010)
• Adult rhGH protocols: lower incidence (Losa 2008)
• Ipamorelin at standard doses: expected to be at the lower end of this spectrum based on lower average GH output, though no dedicated incidence data exists for ipamorelin specifically

Timeline: Thyroid changes, if they occur, develop gradually over weeks to months of continuous use.

Baseline: TSH and free T4 before starting. If TSH is above 2.5 mIU/L at baseline, or if free T4 is low-normal, assess thyroid more thoroughly before proceeding (anti-TPO antibodies, clinical thyroid examination).

During use:

• TSH and free T4 at 8 to 12 weeks from starting, then every 6 months on a long-term protocol
• If symptoms of hypothyroidism develop (fatigue, cold intolerance, weight gain, constipation, dry skin, bradycardia), test TSH immediately regardless of schedule
• If stacking ipamorelin with other GH-axis compounds (CJC-1295 no-DAC, MK-677, exogenous GH), the combined GH burden may increase thyroid monitoring frequency to quarterly

Action thresholds:

• TSH 4.5 to 10 mIU/L with normal free T4: subclinical hypothyroidism; consider levothyroxine if symptomatic, continue monitoring if asymptomatic
• TSH above 10 mIU/L or low free T4: overt hypothyroidism; initiate levothyroxine, reassess peptide dose

Prevention in at-risk users:

• Screen thyroid function before starting any GH peptide protocol
• Address borderline thyroid issues before initiating
• Ensure adequate iodine (150 to 250 mcg/day) and selenium (55 to 200 mcg/day) intake; both are required for thyroid hormone synthesis and D1 activity
• Consider selenomethionine 200 mcg/day supplementation as preventive support on long-term protocols

If subclinical hypothyroidism develops:

• Low-dose levothyroxine (25 to 50 mcg/day) typically normalises TSH without requiring peptide discontinuation
• Replacing T4 substrate that is being accelerated to T3 addresses the mechanism directly
• Thyroid replacement does not negate ipamorelin's GH benefits; adequate thyroid function actually improves the GH response

If switching peptides due to thyroid concerns:

• The pulsatile nature of ipamorelin means thyroid recovery is expected within 4 to 8 weeks of discontinuation as GH levels normalise and D1 activity returns to baseline
• Users who developed subclinical hypothyroidism on sermorelin may find ipamorelin's lower thyroid burden more manageable